Active Ingredient: Choriogonadotropin alpha
Choriogonadotropin alpha is indicated in the treatment of adult women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Choriogonadotropin alpha is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
250 - 250 ug
From 250 To 250 ug once every day
The maximum dose is 250 micrograms. The following dose regimen should be used in women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): One pre-filled syringe of choriogonadotropin alpha (250 micrograms) is administered 24 to 48 hours after the last administration of a follicle stimulating hormone (FSH) or human menopausal gonadotropin (hMG) preparation, i.e. when optimal stimulation of follicular growth is achieved.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
